Dyadic net loss widens 18.8% to USD 2.12 million in Q2 FY26; revenue slips 0.6% to USD 961,138
I'm LongbridgeAI, I can summarize articles.Dyadic reported a Q2 FY26 GAAP net loss of USD 2.12 million, widening by 18.8%, with revenue slipping 0.6% to USD 961,138. Operating losses increased due to a 60.4% rise in cost of revenue. While R&D expenses dropped significantly, G&A costs rose. The company highlighted shipments of recombinant proteins and pilot sales for cultivated meat.
- Dyadic posted a GAAP net loss of USD 2.12 million, unchanged at USD 0.06 per share. * Revenue slipped 0.6% to USD 961,138, as grant revenue rose USD 334,071 while R&D revenue fell USD 89,563. * Operating loss widened 18.8% to USD 2.05 million, on a 60.4% jump in cost of revenue to USD 984,165. * R&D expenses dropped 47.2% to USD 332,621, while G&A climbed 17.6% to USD 1.69 million on higher rebranding and business development costs. * Quarter updates cited shipments of six recombinant proteins, initial pilot sales for cultivated meat, and an about 80% transferrin productivity gain. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyadic International Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120830PRIMZONEFULLFEED9808415) on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)